{"log_id": 6093030573848489304, "direction": 0, "words_result_num": 39, "words_result": [{"probability": {"variance": 0.000442, "average": 0.978977, "min": 0.957953}, "location": {"width": 106, "top": 144, "height": 22, "left": 751}, "words": " czr-hk/CN"}, {"probability": {"variance": 2.9e-05, "average": 0.998104, "min": 0.967522}, "location": {"width": 847, "top": 247, "height": 71, "left": 211}, "words": "关于人类用药过量的资料很少。用药过量最可能的表现将是低血压和心动过速。由于副交"}, {"probability": {"variance": 2.5e-05, "average": 0.995035, "min": 0.98592}, "location": {"width": 100, "top": 247, "height": 28, "left": 179}, "words": "药物过量]"}, {"probability": {"variance": 5.6e-05, "average": 0.996825, "min": 0.95462}, "location": {"width": 844, "top": 290, "height": 72, "left": 172}, "words": "感神经(迷走神经)的兴奋,可发生心跳过缓。如果发生症状性低血压,应该给予支持疗法"}, {"probability": {"variance": 3.2e-05, "average": 0.997488, "min": 0.972939}, "location": {"width": 497, "top": 348, "height": 54, "left": 217}, "words": "氯沙坦及其活性代谢产物都不能通过血液透析而清除"}, {"probability": {"variance": 7.9e-05, "average": 0.993471, "min": 0.977284}, "location": {"width": 104, "top": 414, "height": 27, "left": 180}, "words": "[临床研究]"}, {"probability": {"variance": 0, "average": 0.999231, "min": 0.998317}, "location": {"width": 111, "top": 455, "height": 31, "left": 177}, "words": "高血压研究"}, {"probability": {"variance": 5e-06, "average": 0.998819, "min": 0.987743}, "location": {"width": 883, "top": 469, "height": 70, "left": 179}, "words": "本品抗高血压的疗效已经在11个对照研究中得到证明,其中共有1679名患者服用本品,471"}, {"probability": {"variance": 8.2e-05, "average": 0.996757, "min": 0.944964}, "location": {"width": 884, "top": 497, "height": 70, "left": 180}, "words": "名患者服用安慰剂,488名患者服用其他各类对照药物。轻度和中度原发性高血压患者每天服"}, {"probability": {"variance": 1.8e-05, "average": 0.998326, "min": 0.980118}, "location": {"width": 886, "top": 524, "height": 70, "left": 180}, "words": "用本品,一天一次,其收缩压和舒张压的降低有显著统计学意义;临床研究中的抗高血压治疗"}, {"probability": {"variance": 0.001725, "average": 0.991379, "min": 0.72317}, "location": {"width": 882, "top": 549, "height": 73, "left": 182}, "words": "持续近一年。测定波谷(服药后24小时)和波峰(服药后5-6小时)时的血压,表明其具24"}, {"probability": {"variance": 2.6e-05, "average": 0.998185, "min": 0.96786}, "location": {"width": 886, "top": 576, "height": 73, "left": 184}, "words": "小时平稳的降压作用。抗高血压作用与每天正常生理节律相同。在用药间期末血压降低大约相"}, {"probability": {"variance": 0.009198, "average": 0.974107, "min": 0.505561}, "location": {"width": 873, "top": 607, "height": 67, "left": 184}, "words": "当于服药后5-6小时的70%-80%。首剂用药后3-6周达到最大降压效果。尽管能够显著降低"}, {"probability": {"variance": 2.7e-05, "average": 0.997936, "min": 0.966998}, "location": {"width": 846, "top": 633, "height": 71, "left": 182}, "words": "血压,本品对心率并没有显著临床意义的影响。停用氯沙坦后患者没有出现血压骤然反弹"}, {"probability": {"variance": 0.007383, "average": 0.972342, "min": 0.486234}, "location": {"width": 870, "top": 684, "height": 70, "left": 188}, "words": "日服一次本品50-100mg的降压疗效显著强于日服一次卡托普利50-100mg。日服一次本品"}, {"probability": {"variance": 0.003075, "average": 0.981203, "min": 0.725234}, "location": {"width": 876, "top": 712, "height": 72, "left": 190}, "words": "50mg的降压疗效和日服一次依那普利20mg类似。日服一次本品50-100mg的降压疗效可"}, {"probability": {"variance": 0.003633, "average": 0.988899, "min": 0.594154}, "location": {"width": 866, "top": 741, "height": 68, "left": 192}, "words": "与日服一次阿替洛尔50-100mg的降压效果相比。老年高血压患者(≥65岁),在12周治"}, {"probability": {"variance": 0.001227, "average": 0.989334, "min": 0.838626}, "location": {"width": 724, "top": 775, "height": 63, "left": 191}, "words": "疗后,本品50-100mg日服一次的降压效果与非洛地平缓释剂5-10mg相同"}, {"probability": {"variance": 6.2e-05, "average": 0.996181, "min": 0.965546}, "location": {"width": 871, "top": 820, "height": 68, "left": 193}, "words": "对于男性和女性,年轻(<65岁)和年老(≥65岁)的高血压患者服用本品疗效相同。虽然"}, {"probability": {"variance": 0.005796, "average": 0.986144, "min": 0.506295}, "location": {"width": 870, "top": 850, "height": 66, "left": 195}, "words": "本品对研究的所有种族都有降压疗效,但象其他作用于肾素-血管紧张素系统的药物一样,黑"}, {"probability": {"variance": 4e-06, "average": 0.998453, "min": 0.989892}, "location": {"width": 585, "top": 887, "height": 57, "left": 196}, "words": "人高血压患者对氯沙坦单一治疗的平均反应略低于非黑人患者"}, {"probability": {"variance": 7e-06, "average": 0.998063, "min": 0.990153}, "location": {"width": 498, "top": 943, "height": 52, "left": 197}, "words": "当合并用噻嗪类利尿剂时,本品的降压效果略有增加"}, {"probability": {"variance": 0.002961, "average": 0.983822, "min": 0.696083}, "location": {"width": 873, "top": 977, "height": 71, "left": 200}, "words": "因为本品选择性阻断All体,预计病人服用本品不会引发咳嗽。对使用ACE类药物治疗中"}, {"probability": {"variance": 0.008081, "average": 0.984117, "min": 0.408836}, "location": {"width": 879, "top": 1006, "height": 71, "left": 201}, "words": "出现咳嗽病史的高血压患者进行了一个为期8周的对照研究,服用本品或服用没有ACE类致"}, {"probability": {"variance": 0.006955, "average": 0.983496, "min": 0.457556}, "location": {"width": 862, "top": 1036, "height": 67, "left": 201}, "words": "咳作用的药物(氢氯噻嗪),患者报告咳嗽的发生率近似,显著低于使用ACEl类药物的患"}, {"probability": {"variance": 3e-06, "average": 0.999028, "min": 0.988432}, "location": {"width": 869, "top": 1061, "height": 68, "left": 203}, "words": "者。另外,全面分析16个双盲临床研究的4131名患者,自发报告的咳嗽发生率,服用本品"}, {"probability": {"variance": 0.002374, "average": 0.980719, "min": 0.738414}, "location": {"width": 844, "top": 1090, "height": 67, "left": 205}, "words": "3.1%)和安慰剂(2.6%)或氢氯噻嗪(4.1%)近似,而服用ACE类药物咳嗽发生率则有8.8%"}, {"probability": {"variance": 0.000504, "average": 0.986066, "min": 0.937414}, "location": {"width": 104, "top": 1193, "height": 35, "left": 204}, "words": "LIFE研究"}, {"probability": {"variance": 8.9e-05, "average": 0.996396, "min": 0.948497}, "location": {"width": 845, "top": 1196, "height": 69, "left": 252}, "words": "氯沙坦高血压患者生存研究(LIFE研究)是一项大型、多中心、多国家、随机、三盲、活"}, {"probability": {"variance": 0.000606, "average": 0.993724, "min": 0.833911}, "location": {"width": 890, "top": 1241, "height": 67, "left": 210}, "words": "性药物对照的研究,对9193位年龄为55-80岁(平均67岁)、心电图(ECG)确诊左心室肥"}, {"probability": {"variance": 0.002922, "average": 0.984755, "min": 0.695557}, "location": {"width": 867, "top": 1281, "height": 69, "left": 211}, "words": "厚(LVH)的高血压患者进行研究。入选的患者在基线状况时,1195位(13%)有糖尿病"}, {"probability": {"variance": 0, "average": 0.713178, "min": 0.713178}, "location": {"width": 48, "top": 1284, "height": 46, "left": 1119}, "words": "公"}, {"probability": {"variance": 0.000171, "average": 0.99324, "min": 0.938998}, "location": {"width": 881, "top": 1323, "height": 68, "left": 220}, "words": "326位(14%)有单纯性收缩期高血压;1468位(17%)有冠心病;728位(8%)有脑血管疾"}, {"probability": {"variance": 0.000222, "average": 0.99459, "min": 0.914299}, "location": {"width": 892, "top": 1363, "height": 71, "left": 214}, "words": "病。研究的目的是确定在降血压或超越降血压(测量谷值血压)的益处方面,与阿替洛尔相"}, {"probability": {"variance": 0.0054, "average": 0.981144, "min": 0.57645}, "location": {"width": 893, "top": 1406, "height": 69, "left": 214}, "words": "比,氯沙坦的心血管保护效应。为了达到这个目标,实验设计为2个治疗组的血压控制程度相"}, {"probability": {"variance": 0, "average": 0.73315, "min": 0.73315}, "location": {"width": 20, "top": 1429, "height": 22, "left": 1091}, "words": "C"}, {"probability": {"variance": 0.004198, "average": 0.978122, "min": 0.695151}, "location": {"width": 931, "top": 1435, "height": 83, "left": 217}, "words": "同。患者随机分组,接受每天一次氯沙坦50mg或阿替洛尔50mg治疗。如果目标血压"}, {"probability": {"variance": 0.01982, "average": 0.933594, "min": 0.454407}, "location": {"width": 950, "top": 1485, "height": 73, "left": 221}, "words": "140/90mmHg)未达到,首先可添加氢氯噻嗪(12.5mg)治疗,如需要,氯沙坦或阿替尔的东"}, {"probability": {"variance": 0.020408, "average": 0.910152, "min": 0.640794}, "location": {"width": 219, "top": 1524, "height": 54, "left": 960}, "words": "制药有限公司8"}], "language": 3}